When symptoms of polypharmacy are consistent with those of difficult-to-diagnose disorders, reliable determinations about which drugs are necessary is critical.
AMA J Ethics. 2018;20(12):E1133-1138. doi:
10.1001/amajethics.2018.1133.
Elizabeth A. Sonntag, MD, Keyur B. Shah, MD, and Jason N. Katz, MD
Devices alter heart failure etiology, and specialists must navigate more ethical complexity than ever. How should curricula evolve to help them respond?
AMA J Ethics. 2019;21(5):E407-415. doi:
10.1001/amajethics.2019.407.
Patients have a right to decline or withdraw LVADs. Informed consent and shared decision making is not easy, however, with treatments that are high risk, high reward.
AMA J Ethics. 2019;21(5):E394-400. doi:
10.1001/amajethics.2019.394.
Efrat Lelkes, MD, Angira Patel, MD, MPH, Anna Joong, MD, and Jeffrey G. Gossett, MD
Current policy requires separate informed consent for some Public Health Service increased-risk donors, and this can make shared decision making harder.
AMA J Ethics. 2020;22(5):E401-407. doi:
10.1001/amajethics.2020.401.
